PAM
NWBO

Panagora Asset Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Panagora Asset Management’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-6,036
Closed -$19K – 2436
2015
Q4 		$19K Buy
+6,036
New +$29K ﹤0.01% 2156
2014
Q2 		– Sell
-61,673
Closed -$439K – 2503
2014
Q1 		$439K Buy
+61,673
New +$366K ﹤0.01% 1471

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Panagora Asset Management's NWBO Position: Q1 2016 in Review

Panagora Asset Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2016, closing a stake of 6,036 shares — an estimated $19K sold.

Panagora Asset Management first reported a position in NWBO in Q1 2014 and held it in 2 quarters. The position peaked at $439K in Q1 2014. 74 funds tracked by Wall St. Rank hold NWBO as of Q1 2016.

  • Panagora Asset Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q1 2016 after selling out during the quarter.
  • Panagora Asset Management sold 6,036 Northwest Biotherapeutics, Inc. Common stock shares in Q1 2016, an estimated $19K.
  • Panagora Asset Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2014 and held it in 2 quarters.
  • Panagora Asset Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $439K in Q1 2014.
  • 74 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2016.

Based on Panagora Asset Management's 13F filing for Q1 2016, filed 16 May 2016.